Suppr超能文献

Effect of a direct thrombin inhibitor compared with dalteparin and unfractionated heparin on human osteoblasts.

作者信息

Winkler Tobias, Perka Carsten, Matziolis Dörte, Matziolis Georg

机构信息

Center of Musculoskeletal Surgery, Berlin Brandenburg Center for Regenerative Medicine, Charité - Universitaetsmedizin Berlin, Germany.

出版信息

Open Orthop J. 2011 Mar 16;5:52-8. doi: 10.2174/1874325001105010052.

DOI:10.2174/1874325001105010052
PMID:21552458
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3087215/
Abstract

PURPOSE

Osteoporosis is a relevant problem after long term administration of unfractionated heparin (UFH) and low molecular weight heparin. Melagatran is a representative of a new group of direct thrombin inhibitors with comparable data in the prevention of thromboembolic events after orthopaedic surgery. The aim of our in vitro study was to investigate the effect of a direct thrombin inhibitor compared with dalteparin and UFH on human osteoblasts.

MATERIALS AND METHODS

Melagatran, dalteparin and UFH were added to primary osteoblast cultures in their therapeutic range and two decimal powers below and above. Cell number, protein synthesis, mitochondrial and alkaline phosphatase activity and collagen type I synthesis were evaluated.

RESULTS

Melagatran showed the least influence on protein synthesis and cell proliferation with a reduction of cell number to 83.5 ± 9% (p = 0.027) of the control group only in the highest investigated concentration after 15 days of incubation. Mitochondrial and alkaline phosphatase activity and collagen type I synthesis in osteoblasts incubated with melagatran and dalteparin showed similar patterns. UFH showed the most pronounced influence on cellular metabolism.

CONCLUSIONS

Melagatran showed less inhibitory in vitro effects on human osteoblasts than dalteparin or UFH. The presented study gives first hints that direct thrombin inhibitors may help prevent heparin-induced negative effects on bone metabolism.

摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/61fb/3087215/fd53361f16cf/TOORTHJ-5-52_F1.jpg

相似文献

1
Effect of a direct thrombin inhibitor compared with dalteparin and unfractionated heparin on human osteoblasts.
Open Orthop J. 2011 Mar 16;5:52-8. doi: 10.2174/1874325001105010052.
2
Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts.
Calcif Tissue Int. 2003 Oct;73(4):370-9. doi: 10.1007/s00223-002-2091-5. Epub 2003 Jul 24.
3
Effect of low molecular weight heparin (dalteparin) and fondaparinux (Arixtra) on human osteoblasts in vitro.
Br J Surg. 2005 Feb;92(2):177-83. doi: 10.1002/bjs.4809.
4
Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin.
Thromb Res. 2015 Sep;136(3):658-62. doi: 10.1016/j.thromres.2015.06.034. Epub 2015 Jul 4.
5
Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects.
Blood Coagul Fibrinolysis. 2003 Jul;14(5):457-62. doi: 10.1097/00001721-200307000-00005.
6
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Thromb Haemost. 2002 Feb;87(2):231-7.
7
Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin.
J Am Coll Cardiol. 2002 Mar 6;39(5):811-7. doi: 10.1016/s0735-1097(01)01825-3.
8
Comparative effects of unfractionated heparin and low molecular weight heparin on vascular endothelial cell tissue factor pathway inhibitor release: a model for assessing intrinsic thromboresistance.
J Thromb Thrombolysis. 2002 Oct;14(2):123-9. doi: 10.1023/a:1023280811804.
9
Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties.
Haematologica. 2006 Feb;91(2):207-14.
10
Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.
J Lab Clin Med. 2004 Aug;144(2):100-7. doi: 10.1016/j.lab.2004.04.006.

引用本文的文献

1
Identification of potential cell death-related biomarkers for diagnosis and treatment of osteoporosis.
BMC Musculoskelet Disord. 2024 Mar 25;25(1):235. doi: 10.1186/s12891-024-07349-6.
2
Effect of direct oral anticoagulant dabigatran on early bone healing: An experimental study in rats.
J Adv Periodontol Implant Dent. 2023 Nov 7;15(2):86-92. doi: 10.34172/japid.2023.020. eCollection 2023.
3
Hirudin promotes proliferation and osteogenic differentiation of HBMSCs via activation of cyclic guanosine monophosphate (cGMP)/protein kinase-G (PKG) signaling pathway.
Bioengineered. 2022 Mar;13(3):6061-6069. doi: 10.1080/21655979.2021.2008697.
4
Anticoagulants and Osteoporosis.
Int J Mol Sci. 2019 Oct 24;20(21):5275. doi: 10.3390/ijms20215275.
5
The Effect of Low Molecular Weight Heparins on Fracture Healing.
Open Orthop J. 2015 Jun 26;9:226-36. doi: 10.2174/1874325001509010226. eCollection 2015.

本文引用的文献

1
Ximelagatran--a promising new drug in thromboembolic disorders.
Curr Pharm Des. 2005;11(4):527-38. doi: 10.2174/1381612053382016.
2
Ximelagatran: a novel oral direct thrombin inhibitor for long-term anticoagulation.
Rev Cardiovasc Med. 2004 Spring;5(2):99-103.
3
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
J Thromb Haemost. 2003 Dec;1(12):2490-6. doi: 10.1111/j.1538-7836.2003.00494.x.
4
Changes in bone density during long-term administration of low-molecular-weight heparins or acenocoumarol for secondary prophylaxis of venous thromboembolism.
Pathophysiol Haemost Thromb. 2003 Mar-Apr;33(2):64-7. doi: 10.1159/000073848.
5
Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts.
Calcif Tissue Int. 2003 Oct;73(4):370-9. doi: 10.1007/s00223-002-2091-5. Epub 2003 Jul 24.
6
Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
Thromb Res. 2003 Jul 15;109 Suppl 1:S23-9. doi: 10.1016/s0049-3848(03)00248-2.
7
[Serious complication after subcutaneous injection of heparin for prophylaxis of thromboembolism. Case report].
Unfallchirurg. 2003 Feb;106(2):182-3. doi: 10.1007/s00113-002-0494-4.
8
[Influence of unfractionated and low-molecular-weight heparin on bone healing: an animal model].
Unfallchirurg. 2002 Sep;105(9):791-6. doi: 10.1007/s00113-002-0419-2.
9
Quantification of histochemical staining by color deconvolution.
Anal Quant Cytol Histol. 2001 Aug;23(4):291-9.
10
A histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats.
Blood. 1999 Feb 15;93(4):1231-6.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验